S. Horn

发表

Restoration of SHIP activity in a human leukemia cell line downregulates constitutively activated phosphatidylinositol 3-kinase/Akt/GSK-3β signaling and leads to an increased transit time through the G1 phase of the cell cycle

G. Mayr, M. Jücker, E. Endl, 2004, Leukemia.

An increase in the expression and total activity of endogenous p60c-Src in several factor-independent mutants of a human GM-CSF-dependent leukemia cell line (TF-1)

M. Jücker, S. Horn, Johann Meyer, 2003, Oncogene.

Akt as a therapeutic target in cancer.

Massimo Libra, J. McCubrey, F. Nicoletti, 2008, Expert opinion on therapeutic targets.

Fucoidans as Potential Inhibitors of HIV-1

V. Prassolov, S. Horn, B. Fehse, 2013, Marine drugs.

L 1 . 3 Mutations of the catalytic subunit of class 1 A PI-3 K are constitutively active in hematopoietic cells in vitro and in vivo

J. McCubrey, L. Trümper, A. Martelli, 2008 .

Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms

J. McCubrey, G. Martinelli, A. Martelli, 2010, Leukemia.

Detection of N-RAS and K-RAS in their active GTP-bound form in acute myeloid leukemia without activating RAS mutations

G. Mayr, M. Jücker, W. Fiedler, 2006, Leukemia & lymphoma.

Up‐regulation of the T cell quiescence factor KLF2 in a leukaemic T‐cell line after expression of the inositol 5′‐phosphatase SHIP‐1

G. Mayr, M. Jücker, S. Horn, 2005, British journal of haematology.

Efficient lentiviral transduction and transgene expression in primary human B cells.

S. Horn, B. Fehse, A. Uhde, 2012, Human gene therapy methods.

RUNX1 DNA-binding mutants, associated with minimally differentiated acute myelogenous leukemia, disrupt myeloid differentiation.

F. Buchholz, S. Horn, C. Stocking, 2007, Cancer research.

SHIP1, but not an AML-derived SHIP1 mutant, suppresses myeloid leukemia growth in a xenotransplantation mouse model

M. Schaks, M. Jücker, W. Fiedler, 2017, Gene Therapy.

Characterization of the substrate specificity of the inositol 5-phosphatase SHIP1.

M. Jücker, S. Horn, S. Windhorst, 2020, Biochemical and biophysical research communications.

Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.

Stephen L. Abrams, D. Terrian, J. McCubrey, 2008, Advances in enzyme regulation.

Expression of a mutated form of the p85α regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO)

W. Fiedler, M. Jücker, W. Fiedler, 2002, Leukemia.

Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells

J. McCubrey, L. Trümper, M. Jücker, 2008, Oncogene.

Akt as a therapeutic target in cancer

J. McCubrey, F. Nicoletti, W. Chappell, 2008 .

Defining the oncogenic function of the TEL/AML1 (ETV6/RUNX1) fusion protein in a mouse model

M. Greaves, S. Horn, C. Stocking, 2005, Oncogene.

mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5

J. Hauber, S. Horn, B. Fehse, 2015, Nucleic acids research.

Transient Retrovirus-Based CRISPR/Cas9 All-in-One Particles for Efficient, Targeted Gene Knockout

A. Schambach, D. Heckl, S. Horn, 2018, Molecular therapy. Nucleic acids.

The MADS transcription factor Mef2c is a pivotal modulator of myeloid cell fate.

E. Olson, S. Horn, C. Stocking, 2008, Blood.

Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate.

W. Fiedler, S. Horn, C. Stocking, 2005, Blood.

factor AML, are constitutively active and respond to imatinib mesylate Extracellular KIT receptor mutants, commonly found in core binding

W. Fiedler, S. Horn, C. Stocking, 2013 .

The inositol 5-phosphatase SHIP is expressed as 145 and 135 kDa proteins in blood and bone marrow cells in vivo, whereas carboxyl-truncated forms of SHIP are generated by proteolytic cleavage in vitro

M. Jücker, S. Horn, B. Fehse, 2001, Leukemia.

PKR activity is required for acute leukemic cell maintenance and growth: A role for PKR‐mediated phosphatase activity to regulate GSK‐3 phosphorylation

G. Martinelli, A. Martelli, W. Blalock, 2009, Journal of cellular physiology.

PTEN mediates the cross talk between breast and glial cells in brain metastases leading to rapid disease progression

M. Westphal, K. Pantel, M. Jücker, 2016, Oncotarget.

SHIP1 Is Present but Strongly Downregulated in T-ALL, and after Restoration Suppresses Leukemia Growth in a T-ALL Xenotransplantation Mouse Model

M. Jücker, S. Horn, M. Horstmann, 2023, Cells.

Fucoidans as Potential Inhibitors of HIV-1

V. Prassolov, S. Horn, B. Fehse, 2013, Marine drugs.